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Abstract
Background: The cytological screening programme of Viterbo has completed the second round
of invitations to the entire target population (age 25–64). From a public health perspective, it is
important to know the Pap-test coverage rate and the use of opportunistic screening. The most
commonly used study design is the survey, but the validity of self-reports and the assumptions made
about non respondents are often questioned.
Methods: From the target population, 940 women were sampled, and responded to a telephone
interview about Pap-test utilisation. The answers were compared with the screening program
registry; comparing the dates of Pap-tests reported by both sources. Sensitivity analyses were
performed for coverage over a 36-month period, according to various assumptions regarding non
respondents.
Results: The response rate was 68%. The coverage over 36 months was 86.4% if we assume that
non respondents had the same coverage as respondents, 66% if we assume they were not covered
at all, and 74.6% if we adjust for screening compliance in the non respondents. The sensitivity and
specificity of the question, "have you ever had a Pap test with the screening programme" were
84.5% and 82.2% respectively. The test dates reported in the interview tended to be more recent
than those reported in the registry, but 68% were within 12 months of each other.
Conclusion: Surveys are useful tools to understand the effectiveness of a screening programme
and women's self-report was sufficiently reliable in our setting, but the coverage estimates were
strongly influenced by the assumptions we made regarding non respondents.
Background
The Pap-test is an effective preventive measure in reducing
cervical cancer incidence and mortality [1]. It is recom-
mended by the EU commission guidelines for all women
aged 25–64 once every 3–5 years [2]. These guidelines
also recommend implementing organised screening pro-
grams, because they assure quality control, timeliness of
testing, and equity of access [1,3].
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Italian law requires the operation of screening pro-
grammes in every health district, but some have yet to be
implemented [4]. However, even when a programme is
successful at contacting the entire target population, com-
pliance varies from 20% to 60%, with a mean of 39% (5,
6).
There are several indicators suggesting that most of the tar-
get population undergoes opportunistic Pap-testing and
that the total coverage of the population varies from area
to area. For example, the total annual number of Pap-tests
performed by opportunistic screening in Italy is about
5.000.000, i.e. enough to cover the Italian target popula-
tion of 16.000.000 every three years; but evidence from
the national health survey shows that coverage ranges
from 34% to 78% in the different regions of Italy [7].
In addition to knowing the coverage of the target popula-
tion, it is important to identify the use of opportunistic
screening both in women who are compliant and those
who are not compliant to screening programs: in fact,
addressing inappropriate use of resources is essential to
build an efficient and equitable health service.
For these objectives, the most used study design is the sur-
vey and the most common method used is a telephone
interview [7,8]. Several authors have questioned the valid-
ity of surveys, and in particular two problems have been
highlighted: the validity of recall [9-24] and the assump-
tion about non respondents [25-30].
Objectives of the study
The goals of the survey were to:
Study flow chart Figure 1
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• Estimate the Pap-test coverage in the area of Viterbo
where an organised screening program is active.
• Identify the reasons for non compliance to the screening
invitation.
We addressed the following methodological issues in ana-
lysing these data:
• We assessed the validity of the women's recall.
• We propose a sensitivity analysis on the assumptions
about the non respondents.
• We developed a method to estimate the role of address
accuracy in screening compliance.
Methods
The setting
The Viterbo Health District is a rural area in central Italy
with 291.000 inhabitants (target population 81.000 25–
64 year old women). The screening program in Viterbo
started in 1997 and the second round finished in the sum-
mer of 2004. Every three years it invites all female resi-
dents aged 25–64 in the area to be screened. The average
compliance is 42%. All mailings, reminders, Pap-tests,
colposcopies, histological samples and treatments are
recorded individually in the program database.
Study design
This is a study integrating data from a cross-sectional sur-
vey and from the screening program registry (figure 1). We
sampled 940 women aged 25–64, from the list of resi-
dents in the Health District, in two strata: residents of the
city of Viterbo and residents of the rest of the district.
The sample size was determined to have a power of 80%,
with alpha 0.05, to detect a 10% difference in coverage
between the two population groups, with a mean preva-
lence of 50%, the smallest group representing at least 30%
of the sample. The resulting sample size is 600; the
expected response rate was 65%. The resulting precision
for a point estimate of a hypothetical 50% coverage is +/-
2%.
The questionnaire
The questionnaire included the following sections: indi-
vidual data (educational level, occupation, employment);
hysterectomy; family history of cancer; screening history
(when and where of last Pap-test; test frequency); reasons
for not complying with screening program; satisfaction
with service. The phone questionnaire took about 15 min-
utes, and was conducted by three trained interviewers. The
survey was conducted between May and October 2004.
All women sampled were phoned up to 9 times, then a
reminder was mailed to the women who had not yet been
contacted, after which another 3 phone contacts were
made. The phone calls were made at different hours of the
day.
Analysis
The information collected in the interview about Pap-tests
performed by the screening program was compared with
the data in the screening archives.
We used an algorithm to estimate the proportion of
women unreachable for screening, (31) based on the fol-
lowing assumptions: 1) that we have the correct addresses
and phone numbers of the women who have been com-
pliant to screening at least once, but may not for women
who were never screened; 2) that the difference between
the proportion of not contacted women among the non-
compliant women and the proportion of not contacted
women among the compliant is due to the wrong
addresses (and consequently phone numbers) in the non-
compliant women; 3) that the women are honest when
stating they have received the screening invitation letter;
4) and that the entire sampled population has been
invited at least once. The resulting algorithm for the pro-
Results of the sensitivity analysis for 36-month coverage esti- mates Figure 2
Results of the sensitivity analysis for 36-month coverage esti-
mates. Hypothesis 1: crude coverage (hypothesis non-
respondents = respondents); hypothesis 2: coverage in the 
non-respondents adjusted by screening compliance, i.e. cov-
erage among non-respondents = (observed coverage among 
screening non-compliant)*(proportion of non-compliant 
among non-respondents)+(observed coverage among 
screening compliant)*(proportion of non-compliant among 
non-respondents); hypothesis 3: all the non-respondents 
non-compliant to screening are not covered and only the 
compliant are covered. The bars represent the 95% confi-
dence interval.
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portion of unreachable women is: (% of women who
never received the letter)+((% of women not contacted in
the group of the non compliant to screening)-(% not con-
tacted in the screening compliant group)).
We performed a sensitivity analysis for 36-month cover-
age and used three estimates according to different
hypotheses on non-respondents:
1. We considered crude coverage (hypothesis: non-
respondents = respondents), the least conservative
hypothesis;
2. The intermediate hypothesis adjusted the coverage of
non-respondents by screening compliance: coverage
among non-respondents to the interview = (observed cov-
erage among screening non-compliant)*(proportion of
non-compliant among non-respondents)+(observed cov-
erage among screening compliant)*(proportion of non-
compliant among non-respondents);
3. In the third and most conservative hypothesis only the
compliant are considered covered, so all non-respondents
who were not compliant to screening are considered not
covered.
Ethics and privacy
The Regional Ethics Committee stated that the Screening
Program of each Health District must provide a Pap-test
every three years to all residents in the target population,
and this task involves the ascertainment of actual cover-
age.
The interviews were anonymous, only a personal identifi-
cation number, internal to the Screening Program data-
base, permitted the linkage with screening history records.
Results
Response rate
We interviewed 641 women out of 940 sampled (68.2%),
6% refused to participate and 25.9% were unreachable.
We did not find any difference in the response rate by age
or residence.
We sampled 455 women who had had at least one Pap-
test in the screening program and 485 who never com-
plied with screening. We observed a highly significant dif-
ference in response rate between the screening compliant
and the non-compliant: we interviewed 84.2% of the
screening compliant women and 53.2% of the non com-
pliant; the difference was mostly due to the unreachable
women (12.3% vs. 38.6%), rather than to refusals (3.5%
vs. 8.3%).
Pap-test coverage
We excluded from the analysis 22 (3.4%) women who
had had a hysterectomy. Fifty-nine declared to never have
had a Pap-test in their life, the crude coverage once in a
lifetime is 90.1% (95%CI 87.3–92.8); only one woman
stated that she did not know what a Pap-test is. Eighty-six
point four percent (95%CI 83.3 – 89.5) reported having
had a Pap within 36 months, and 88.5% (95%CI 85.6 –
91.4) within 60 months. We asked the compliant women
what their Pap-test history was at their first appointment
with the screening program, and 217 women answered:
Table 1: Test periodicity. How frequently the women declared to repeat Pap-test in months, by type of provider.
Private Public
M o n t h s N%N%
3 0 0,0 1 0,3
6 8 3,8 2 0,6
12 129 60,6 97 28,0
1 510 , 520 , 6
1 862 , 861 , 7
24 39 18,3 64 18,4
36 24 11,3 168 48,4
4 820 , 910 , 3
6 010 , 530 , 9
7 210 , 520 , 6
8 410 , 510 , 3
120 1 0,5 0 0,0
Total 213 100,0 347 100,0BMC Health Services Research 2006, 6:36 http://www.biomedcentral.com/1472-6963/6/36
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18% (40) never had a Pap-test previously, only 5 of them
were 25 years old at the time of the first invitation; 32%
(70) had a Pap-test more than three years before.
We performed a sensitivity analysis of coverage at 36-
months according to our different hypotheses on the cov-
erage among non-respondent women. The coverage
among screening compliant was 92.4%, among non-com-
pliant 69.0%; after adjusting for screening compliance the
predicted coverage among non-respondents was 74.6%
and 82.4% in the general population; according to the
most conservative hypothesis, i.e. none of the non com-
pliant who did not respond were covered, the estimate is
66.0% (figure 2).
The multivariate analysis showed a strong association
with age, (women under 30 years old were less likely to be
covered) and a weak association with having more than 5
years of education. We did not observe an association
with residence.
Tables 1 and 2 show the distribution of the answers to the
question "when did you have your last Pap-test" and
"how frequently do you have Pap-tests", by type of pro-
vider. Women who were last tested by a public provider
tended to have a bimodal distribution with peaks at one
and at three year periods (the periods used by the screen-
ing programme and recommended by the National
Health Service Guidelines), while the women who had
their last Pap-test in a private clinic had a single peak at
one year.
Reasons for non compliance to screening invitation
The first reason for non compliance is not receiving the
letter. We estimated the proportion of unreachable
women, using the algorithm described in the methods:
the not-reached proportion of the non compliant
(38.6%), minus the not-reached proportion of the com-
pliant (12.3%), plus those who reported not receiving the
letter (9%). About 35% of the not compliant were not
screened because they did not receive the invitation, cor-
responding to 20% of the general population.
Table 3 summarises the self-reported reasons for non
compliance to screening invitation, by last Pap-test:
women who never had a Pap reported "fear" as the main
reason, while women who had had a Pap in the private
sector reported "no trust in public services" or "exclusive
trust in private gynaecologist".
Just over half of the interviewed women who had had at
least one Pap-test were tested most recently by the screen-
ing programme, 10.9% in another public clinic and
38.0% in a private clinic. We asked all women who had
had their most recent Pap outside the screening program
if they had ever had a Pap in the screening programme:
30% of them also had had a Pap in the screening program,
a proportion that was higher in women who visit public
clinics (43%).
We measured the women's satisfaction with the test pro-
cedures (figure 3). Women who had the Pap in a private
clinic were significantly more satisfied than women who
were screened (90.0% vs 79.6%, chi2 = 9.7; p = 0.002),
particularly those who had been tested in both places
(90.0% vs. 51.7%, chi2 = 24.7: p < 0.00005). We did not
observe differences in satisfaction by age, residence or
educational level.
Validity of self-report (recall)
We compared the information from the screening registry
with the answers given to the interview. Table 4 shows the
sensitivity (84.5%; 95%CI 80.9–88.3) and specificity
(82.2%; 95%CI 76.9–86.6) of the question "ever had a
Pap-test in the screening program".
Figure 4 shows the difference in months between the self-
reported Pap-test date and the date reported in the screen-
ing registry. The variable was present for the 267 women
who reported having had their last Pap in the screening
Table 2: Self reported time elapsed from the last Pap-test in months, by type of provider.
Private Public
M o n t h s N%N%
0–12 154 72,6 231 66,6
13–24 40 18,9 88 25,4
19–24 32 15,1 73 21,0
25–36 12 5,7 11 3,2
37–48 2 0,9 6 1,7
49–60 2 0,9 5 1,4
61+ 2 0,9 6 1,7
Total 212 100,0 347 100,0BMC Health Services Research 2006, 6:36 http://www.biomedcentral.com/1472-6963/6/36
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program that was recorded in the screening registries. The
mode of the distribution was +/- 1 month, 68% of the
observations fell between +/- 12 months. There was asym-
metry in the distribution: the self reported dates tended to
be more recent than the dates in the registry.
Discussion
Surveys to measure test coverage for cancer prevention
have been conducted in several countries [8] to monitor
the efficacy of information campaigns and to understand
non compliance to screening. In Italy however, although
public screening programmes have been activated in
almost all parts of the country, the compliance to screen-
ing programs is low in many districts. The question is:
what is the real Pap-test coverage rate? The National
Health Interview gives an estimate of 68% for the country,
and 77% for our region [7].
We tried to answer this question with this study, in
response to a mandate from the Italian Group for Cyto-
logical Screening, but also had to address several method-
ological issues common to all surveys that try to estimate
the coverage achieved by screening tests.
The coverage
Our estimate for Pap-test coverage once in a lifetime is
90%, while the National Health Interview of 1999–2000
found it to be 77% in our region [7]. This difference is
probably due to a real increasing trend in the area, conse-
quent to cultural changes and to the activation of the first
round of public screening in 1998–2001 that invited the
entire target population and was promoted locally. We
know that 50% of the women at their first appointment
with the screening program were not adequately covered,
consequently, because the compliance to screening was
about 42%, the impact of the program showed an increase
of at least 20% of the actual coverage.
The coverage estimate changes according to the assump-
tion we used regarding the non respondents. This prob-
lem has been addressed in many surveys [25,29,32-34]. In
this case, we were fortunate to know the Pap-test status for
about 45% of the target population from the screening
registries. Combining the information from the survey
with that from the screening registry we observed that: 1)
the non respondent population is very different from the
respondent population regarding their utilisation of
screening; 2) the unadjusted results of the survey overesti-
mate Pap-test coverage. For the sensitivity analysis we
used three different hypotheses. For the intermediate
hypothesis, we adjusted for screening compliance assum-
ing that the non respondent women compliant to screen-
ing have the same coverage as the respondents compliant
to screening, and that the non-respondent women non-
compliant to screening have the same coverage as the
Table 3: Self-reported reasons for non compliance to screening invitation, by provider of last Pap-test.
private public never screened
reasons for non compliance N % N % N %
did not receive the letter 21 9,9 8 13,1 10 16,9
Forgot 40 18,8 27 44,3 22 37,3
pregnancy 10 4,7 1 1,6
no trust in public health services 13 6,1 1 1,7
exclusive trust in private gynaecologist 62 29,1
Fear 8 3,8 16 27,1
did not consider important 58 , 5
hysterectomized 11 , 7
Illness 11 , 7
Virgin 35 , 1
do not respond 59 27,7 25 41,0
Total 213 100,0 61 59 100,0
Table 4: Sensitivity and specificity of the phone interview 
question "Have you ever had a Pap-test performed by the public 
screening programme?", according to the screening registry.
screening registry
phone interview yes no total
yes 325 46 371
no 58 212 270
total 383 258 641
sensitivity specificity
84.5% 82.2%BMC Health Services Research 2006, 6:36 http://www.biomedcentral.com/1472-6963/6/36
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respondent non-compliant to screening. This method
gives results similar to those from other surveys interview-
ing only non compliant women, proposed by several
authors that was used to estimate the Pap-test coverage in
areas where screening programs are active and have a reg-
istry available [35,36].
The provider and the periodicity were associated: women
who had their last Pap in a private clinic repeated Pap-
tests more frequently than women who were last tested by
the screening program. Given the cross-sectional design
we cannot affirm that the provider influences the
women's behaviour; it could be a self selection effect:
women who want more Pap-tests go to private clinics
because the screening programme only provides one Pap
every three years. Nevertheless, although we cannot say
that the screening program decreases over-screening, we
can affirm that it is associated with more appropriate tim-
ing.
Reasons for non compliance
The major barrier to screening was the low reliability of
the address list for mailing the invitations, in fact, we esti-
mated that 21% of the women could not be reached.
The algorithm we used to estimate the proportion of
women who were unreachable is simple and is based on
reasonable, although not perfect assumptions. This
method however, in our opinion, is useful since there are
no other simple solutions to assess the quality of the
address lists.
The second reason for non compliance is the lack of trust
in public service, an old problem in some areas of central
and southern Italy.
Even though 75% of women were satisfied with the
screening programme, it is significantly worse than for
private providers; particularly concerning is the low satis-
faction with screening in women who had been both pri-
vately tested and screened. We have no indications about
the reasons for the dissatisfaction, but it may be intrinsic
to the organisation of our and other mass screening pro-
grams where the physician does not reassure the patients
[37] during the sampling, and negative results are com-
municated only by a mail, about one month later.
Methodological remarks and limits
The validity of self-reported information about Pap-tests
has been studied in several surveys, which have reached
Women's satisfaction according to the Pap-test provider Figure 3
Women's satisfaction according to the Pap-test provider.
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different conclusions. It is evident from most of these
studies that the validity of women's recall varies according
to the socio-economic and cultural environment, so the
results change according to geographical area, ethnicity,
type of health care provider, and even neighbourhood
[9,10,13,15-17]. Most of the literature about this topic has
been published in the US, in order to validate the results
of the NHIS [38] and other surveys [39] used to measure
the progress in cancer prevention and the achievement of
the National Cancer Institute goals. Few European studies
have been published [40], and none in Italy recently (36,
41–43). In our population the validity of self-reported
Pap-tests is high and only slightly overestimated coverage,
because the sensitivity and the specificity are similar. The
effect of telescoping [44], the tendency to report a test as
having occurred more recently than it actually did, is
modest, nevertheless it must be taken into account that
when the source of information to measure three years
coverage is women's recall, what is actually being meas-
ured is the percentage of women who had a Pap-test in the
last 30–48 months. The district of Viterbo is mainly rural,
with a pro-capita yearly income close to the Italian mean
(24,000 €), the educational level of the population is sim-
ilar (9% did not complete middle school and 31% have a
high school degree; the national figures are 10% and 33%,
data from the National Institute of Statistics – ISTAT), and
it has an immigrant population of 3.4% (the Italian aver-
age is 3.5%). This picture of the study population is con-
sistent with the results about validity [18,45]. The major,
and unavoidable, limit of our study for validating the self-
reports is that we can only validate the tests performed
within the screening programme, not those performed
Frequency distribution of the difference between the self reported Pap-test dates and the dates reported in the screening reg- istry Figure 4
Frequency distribution of the difference between the self reported Pap-test dates and the dates reported in the screening reg-
istry. A positive value indicates that the woman's reported date was more recent than the registry date. The variable is defined 
for the 267 women who declared to have had the last Pap in the screening programme and had a Pap recorded in the screening 
registries.
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privately or in other settings that have no registries, never-
theless we do not see any reason for which women should
preferentially forget the tests performed in a screening
program or in another provider.
Conclusion
Surveys are a useful tool to determine the effectiveness of
a screening program in maintaining high Pap-test cover-
age, but the coverage estimates we can obtain are strongly
influenced by the assumptions we make about non-
respondents. Adjusting for screening compliance among
non respondents give a more sound estimate than assum-
ing equal coverage in respondents and non respondents.
In our setting the most important reason for non compli-
ance to screening is that we were unable to contact 20% of
the target population: every effort possible should be
made to obtain reliable address lists.
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